Selected Publications

1. Tetsu O, McCormick F (1999). b-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-6.

2. Wakita K, Tetsu O, McCormick F (2001). A mammalian two-hybrid system for APC-mutated colon cancer therapeutics. Cancer Research 61, 854-8.

3. Wakita K, McCormick F, Tetsu O (2001). Method for screening ecdysone inducible stable cell lines. BioTechniques 31, 414-8.

4. Tetsu O, McCormick F (2003). Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3, 233-45.

5. Rodriguez-Viciana P*, Tetsu O*, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. (2006). Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneoussyndrome. Science 311:1287-90. (* co-first author)

6. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. (2006). A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 1 e128, 1-12.

7. Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O. (2008). Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: Implications for therapeutic options. Hum Mol Genet. 17: 419-30.

8. Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2.
Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O.
Plos One. 2009 Jun 25;4(6):e6040